Positive topline results reported for Oxurion’s DME treatment

Oxurion’s plasma kallikrein inhibitor treatment candidate for diabetic macular edema was safe and well-tolerated in a phase 1 study.

A single intravitreal injection of THR-149 at three ascending dose levels in 12 DME patients also showed an improvement in best corrected visual acuity of up to 7.5 letters at day 14 and an average improvement of 6.5 letters at day 90, according to a press release.

“We are delighted by these encouraging topline data, which confirm that THR-149 is not only well-tolerated and safe for intravitreal use, but also provides a rapid and sustained gain in BCVA,” Oxurion CEO Patrik De Haes, MD, said in the release. “These positive findings provide us with the information and confidence needed to plan the next stage of THR-149’s clinical development. They also demonstrate that THR-149 has the potential to become the best-in-class PKal inhibitor for the treatment of DME.”

A complete analysis of the phase 1 open-label, multicenter, nonrandomized trial is expected to be presented at the Euretina and American Academy of Ophthalmology meetings this fall, the release said.

Oxurion’s plasma kallikrein inhibitor treatment candidate for diabetic macular edema was safe and well-tolerated in a phase 1 study.

A single intravitreal injection of THR-149 at three ascending dose levels in 12 DME patients also showed an improvement in best corrected visual acuity of up to 7.5 letters at day 14 and an average improvement of 6.5 letters at day 90, according to a press release.

“We are delighted by these encouraging topline data, which confirm that THR-149 is not only well-tolerated and safe for intravitreal use, but also provides a rapid and sustained gain in BCVA,” Oxurion CEO Patrik De Haes, MD, said in the release. “These positive findings provide us with the information and confidence needed to plan the next stage of THR-149’s clinical development. They also demonstrate that THR-149 has the potential to become the best-in-class PKal inhibitor for the treatment of DME.”

A complete analysis of the phase 1 open-label, multicenter, nonrandomized trial is expected to be presented at the Euretina and American Academy of Ophthalmology meetings this fall, the release said.